PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
LNTH vs. VRTX
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between LNTH and VRTX is 0.23, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

LNTH vs. VRTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Lantheus Holdings, Inc. (LNTH) and Vertex Pharmaceuticals Incorporated (VRTX). The values are adjusted to include any dividend payments, if applicable.

-30.00%-20.00%-10.00%0.00%10.00%AugustSeptemberOctoberNovemberDecember2025
-21.68%
-14.15%
LNTH
VRTX

Key characteristics

Sharpe Ratio

LNTH:

1.08

VRTX:

-0.11

Sortino Ratio

LNTH:

2.11

VRTX:

0.02

Omega Ratio

LNTH:

1.29

VRTX:

1.00

Calmar Ratio

LNTH:

1.34

VRTX:

-0.12

Martin Ratio

LNTH:

4.26

VRTX:

-0.32

Ulcer Index

LNTH:

15.38%

VRTX:

8.56%

Daily Std Dev

LNTH:

60.77%

VRTX:

24.76%

Max Drawdown

LNTH:

-78.62%

VRTX:

-91.77%

Current Drawdown

LNTH:

-26.01%

VRTX:

-18.33%

Fundamentals

Market Cap

LNTH:

$6.36B

VRTX:

$108.68B

EPS

LNTH:

$6.01

VRTX:

-$1.94

PEG Ratio

LNTH:

0.61

VRTX:

1.10

Total Revenue (TTM)

LNTH:

$1.14B

VRTX:

$8.09B

Gross Profit (TTM)

LNTH:

$749.68M

VRTX:

$6.99B

EBITDA (TTM)

LNTH:

$493.72M

VRTX:

-$699.50M

Returns By Period

In the year-to-date period, LNTH achieves a 2.25% return, which is significantly lower than VRTX's 4.79% return.


LNTH

YTD

2.25%

1M

0.35%

6M

-21.68%

1Y

66.22%

5Y*

37.16%

10Y*

N/A

VRTX

YTD

4.79%

1M

-5.70%

6M

-14.15%

1Y

-2.54%

5Y*

12.37%

10Y*

12.99%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

LNTH vs. VRTX — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LNTH
The Risk-Adjusted Performance Rank of LNTH is 8282
Overall Rank
The Sharpe Ratio Rank of LNTH is 8080
Sharpe Ratio Rank
The Sortino Ratio Rank of LNTH is 8282
Sortino Ratio Rank
The Omega Ratio Rank of LNTH is 8383
Omega Ratio Rank
The Calmar Ratio Rank of LNTH is 8484
Calmar Ratio Rank
The Martin Ratio Rank of LNTH is 7979
Martin Ratio Rank

VRTX
The Risk-Adjusted Performance Rank of VRTX is 3636
Overall Rank
The Sharpe Ratio Rank of VRTX is 4040
Sharpe Ratio Rank
The Sortino Ratio Rank of VRTX is 3333
Sortino Ratio Rank
The Omega Ratio Rank of VRTX is 3232
Omega Ratio Rank
The Calmar Ratio Rank of VRTX is 3838
Calmar Ratio Rank
The Martin Ratio Rank of VRTX is 3939
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

LNTH vs. VRTX - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Lantheus Holdings, Inc. (LNTH) and Vertex Pharmaceuticals Incorporated (VRTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for LNTH, currently valued at 1.08, compared to the broader market-2.000.002.004.001.08-0.11
The chart of Sortino ratio for LNTH, currently valued at 2.11, compared to the broader market-4.00-2.000.002.004.002.110.02
The chart of Omega ratio for LNTH, currently valued at 1.29, compared to the broader market0.501.001.502.001.291.00
The chart of Calmar ratio for LNTH, currently valued at 1.34, compared to the broader market0.002.004.006.001.34-0.12
The chart of Martin ratio for LNTH, currently valued at 4.26, compared to the broader market-10.000.0010.0020.0030.004.26-0.32
LNTH
VRTX

The current LNTH Sharpe Ratio is 1.08, which is higher than the VRTX Sharpe Ratio of -0.11. The chart below compares the historical Sharpe Ratios of LNTH and VRTX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.000.501.001.502.00AugustSeptemberOctoberNovemberDecember2025
1.08
-0.11
LNTH
VRTX

Dividends

LNTH vs. VRTX - Dividend Comparison

Neither LNTH nor VRTX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

LNTH vs. VRTX - Drawdown Comparison

The maximum LNTH drawdown since its inception was -78.62%, smaller than the maximum VRTX drawdown of -91.77%. Use the drawdown chart below to compare losses from any high point for LNTH and VRTX. For additional features, visit the drawdowns tool.


-40.00%-30.00%-20.00%-10.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-26.01%
-18.33%
LNTH
VRTX

Volatility

LNTH vs. VRTX - Volatility Comparison

The current volatility for Lantheus Holdings, Inc. (LNTH) is 9.38%, while Vertex Pharmaceuticals Incorporated (VRTX) has a volatility of 14.28%. This indicates that LNTH experiences smaller price fluctuations and is considered to be less risky than VRTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%AugustSeptemberOctoberNovemberDecember2025
9.38%
14.28%
LNTH
VRTX

Financials

LNTH vs. VRTX - Financials Comparison

This section allows you to compare key financial metrics between Lantheus Holdings, Inc. and Vertex Pharmaceuticals Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab